|
我查到的有关脑癌的资料：
IRESSA ： 有效率27%
TARCEVA： 有效率40%+
反映停：有效 ，(注意，应为晚上服用)
文献如下：
Thalidomide For Brain Tumors反映停(沙利度胺)治疗脑肿瘤
By Jon Glass, MD
NYU Medical Center
New York , NY
Phone: 212-263-6267 Fax: 212-263-5715
E-mail: jglassmd@pol.net
Last Updated: 2/99 
Thalidomide was used widely outside of the United States as a
hypnotic/sedative agent in the late 1950s and the early 1960s, but was
withdrawn from the market because of the high incidence of severe birth
defects attributed to this drug. Thalidomide was never approved in the
US until recently, when it was approved for use in the treatment of
leprosy-related conditions. However, there has been renewed interest in
thalidomide over the past several years, particularly in the treatment
of AIDS-related conditions, cancer and HIV-induced wasting,
complications of leprosy, and bone-marrow transplant related
graft-versus-host disease. These effects were attributed mostly to
specific inhibitory activity on tumor necrosis factor-alpha (TNF-alpha)
production.
Observations that thalidomide is also an inhibitor of angiogenesis
(prevents formation of new blood vessels in tumors) has prompted
investigations of its use in the treatment of cancer. In order for a
rapidly growing tumor to maintain its growth, a tumor "signals" already
existing blood vessels to sprout new branches to feed it. Without a
supply of oxygen and other nutrients, tumor growth would be impaired.
As a tumor continues to grow, additional blood vessels would need to be
formed to sustain new areas of tumor growth.
Clinical
trials of thalidomide as a single agent in malignant gliomas that have
recurred following radiation therapy have shown evidence of that this
drug is active and can produce responses.(临床试验中，反映停作为单一剂，在恶性胶质瘤放射治疗有复发后，已显示出证据的此药是积极的和能够产生反应) Thalidomide is currently
being tested in combination with a chemotheraputic agent active in
malignant gliomas (carboplatin), and single-agent clinical trials are
being initiated in the treatment of recurrent brain metastases and in
the treatment of recurrent atypical or malignant meningiomas.
Thalidomide
is an oral agent. In the ongoing clinical trials for gliomas,
meningiomas, and brain metastases, it is taken as a single dose at
night. (沙利度胺是一种口服剂。在目前正在进行临床试验，为脑胶质瘤，脑膜瘤，脑转移瘤，它是作为一个单一的剂量是在夜间进行。)The dose administered is dependent on the trial and is based on
body surface area. Toxicities are usually dose-dependent and include
drowsiness and constipation (most common) as well as rash and
neuropathy (nerve damage) in the arms and legs. The most serious
toxicity is the damage that thalidomide can produce in a developing
fetus. All women receiving this drug require monthly pregnancy tests
(unless not medically necessary). All men and women receiving
thalidomide are required to use at least two forms (barrier and
hormonal) of contraception.
[此贴子已经被作者于2007-11-5 16:01:20编辑过] | 
IP卡
狗仔卡
发表于 2007-11-3 09:51:34
显身卡
楼主